Editorial: Recent advances in the development of vaccines against Acinetobacter baumannii
Bibliographic record
Abstract
Recent advances in the development of vaccines against Acinetobacter baumanniiAcinetobacter baumannii is a notorious Gram-negative healthcare-associated (nosocomial and community-acquired) bacterial pathogen that causes a high mortality rate (up to 70%).The rapid emergence of highly antibiotic-resistant strains is a further propellant to introduce the bacterium as a serious public health threat.Hence, the World Health Organisation (WHO) listed A. baumannii (carbapenem-resistant) as the first priority that needs new antibiotics.The recent coronavirus disease 2019 (COVID-19) pandemic further increased the outbreak of carbapenem-resistant A. baumannii infections.Many novel antibiotics were introduced into the market but few are effective against A. baumannii.Hence, further approaches such as immunization trials had been considered as alternative solutions against A. baumannii infections.Several antigens had been introduced for active and passive immunizations.An effective robust immunization should develop full protection against various types of infections and all pathogenic strains.Moreover, it should have no deleterious effect on microbiota as well as the human proteome.Despite rigorous basic and pre-clinical studies conducted on active and passive immunizations against this pathogen, no vaccine has been advanced to clinical trials.Recently, the combination of protective antigens (1, 2), epitopes/peptides (3) or presentation of protective epitopes by appropriate scaffold (4) had been suggested as effective promising approaches against A. baumannii.In this Research Topic, 4 research articles and one review article on recent advances in the development of vaccines against A. baumannii are collected.Sun et al. conducted a study in which a 39-amino acid extracellular peptide from Cterminal of Ata was fused to the cholera toxin B subunit (CTB), as immunoadjuvant.The construct elicited both Th1 and Th2 immune responses in mice with no overt inflammation.Immunized mice showed a significant decrease in the blood and tissue bacterial loads.A broad protection against a variety of A. baumannii strains was also Frontiers in Immunology frontiersin.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.013 |
| Meta-epidemiology (narrow) | 0.003 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.002 | 0.002 |
| Scholarly communication | 0.005 | 0.004 |
| Open science | 0.003 | 0.001 |
| Research integrity | 0.008 | 0.013 |
| Insufficient payload (model declined to judge) | 0.014 | 0.012 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".